A national organization that promotes drug-free workplaces and a pharmaceutical company that specializes in cannabinoids filed a petition in federal court on June 9 to try to stop the Trump administration’s immediate devolution of medical cannabis.

The National Drug and Alcohol Administration Association (NDASA) and MMJ International Holdings, whose subsidiary has an active DEA Schedule I analytical laboratory registration, asked the U.S. Court of Appeals for the District of Columbia Circuit on April 22 to stop U.S. Attorney General Todd Blanche from acting. signed an order reclassifying the state license for medical cannabis to Schedule III until the court case to set aside the entire order is decided.

The plaintiffs argue that the court must consider four factors:

1. A lawsuit between the human rights group NORML and the Drug Enforcement Administration (DEA) nearly 50 years ago;
2. The transfer order “illegally” bypassed regulatory notice and comment;
3. Two plaintiffs will “suffer irreparable harm” without a stay; and
4. The balance of equity and public interest.

To read the rest of this article on Cannabis Business Times, Click here

Post Parties opposing deadline ask court to delay Schedule III cannabis order first appeared on Marijuana Retail Report – News and information for cannabis retailers.